| Multi-Omics Profiling of Per- and Polyfluoroalkyl Substances and Chemical Exposures in Relation to Bladder and Upper Tract Urothelial Cancer Risk |
Jongeun Rhee |
Henry M. Jackson Foundation for the Advancement of Military Medicine (Center for Prostate Disease Research, Murtha Cancer Center Research Program) |
MACS |
Aug 17, 2026 |
2026-0140 |
| Serum concentrations of per- and polyfluoroalkyl substances and kidney cancer risk: A nested case-control study among military aviators and aviation support personnel |
Jonathan Hofmann |
National Cancer Institute |
MACS |
Aug 17, 2026 |
2026-0131 |
| Imaging-Based Mortality Prediction in the National Lung Screening Trial |
Metin Gurcan |
Wake Forest University Health Sciences |
NLST |
Jul 27, 2026 |
NLST-1524 |
| Developing scalable machine learning-based approaches to classifying significant incidental findings in patients undergoing lung cancer screening |
Ilana Gareen |
Brown University |
NLST |
Jul 20, 2026 |
NLST-1517 |
| AEGIS — AI-Enabled Genomic and Integrated Stratification for Multi-Cancer Risk: Deep-Learning Development and Internal Validation in the PLCO Cohort |
Aneel Paulus |
West Eastern Health |
PLCO |
Jul 14, 2026 |
PLCO-2064 |
| Development of generalizable pathology foundation models for cancer prognosis using PLCO whole slide images |
Marvin Lerousseau |
Spotlight Medical, SAS |
PLCO |
Jul 14, 2026 |
PLCOI-2060 |
| External Validation of a Deep-Learning Atypical Mitosis Based Prognostic Model Using the PLCO Pathology Image Repository |
William Chen |
University of California, San Francisco |
PLCO |
Jul 14, 2026 |
PLCOI-2059 |
| Developing a risk prediction model for future colorectal neoplasia |
AASMA SHAUKAT |
NYU Langone Health |
PLCO |
Jul 14, 2026 |
PLCOI-2062 |
| NeuroAI-PLCO Images: Longitudinal Risk Stratification Using PLCO Imaging and Structured Data |
Richard Tran |
Trove-AI |
PLCO |
Jul 14, 2026 |
PLCOI-2056 |
| Developing Quantitative AI-histologic Signatures Associated with Prognosis and Treatment Benefit Across Cancer Types in the PLCO Trial |
Haochen Zhang |
Valar Labs |
PLCO |
Jul 14, 2026 |
PLCOI-2054 |
| Wildfire Smoke Exposure and Cancer-Related Outcomes in the NLST Cohort |
Shuguang Leng |
University of New Mexico |
NLST |
Jul 14, 2026 |
NLST-1518 |
| Vision–Language Learning for Generalizable Pulmonary Nodule Characterization in Low-Dose CT Screening |
Benjamin Wild |
Berlin Institute of Health at Charité |
NLST |
Jul 14, 2026 |
NLST-1521 |
| AEGIS-Lung — Deep-Learning Development and Internal Validation of an Integrated Lung-Cancer Risk Model in the NLST Cohort |
Aneel Paulus |
West Eastern Health |
NLST |
Jul 14, 2026 |
NLST-1522 |
| NeuroAI-Lung: Longitudinal Risk Stratification Using NLST Low-Dose CT Data |
Richard Tran |
Trove-AI |
NLST |
Jul 14, 2026 |
NLST-1519 |
| PLCO Germline Materials for Integrated Whole-Genome Discovery of Lung Cancer Susceptibility with the Sherlock-Lung Study |
Maria Teresa Landi |
National Cancer Institute, National Institutes of Health |
PLCO |
Jul 8, 2026 |
2026-0117 |
| Repurposing: Efficient use of excess PLCO biospecimens to investigate DNA methylation patterns and cardiovascular disease mortality risk |
Jason Wong |
National Heart Lung and Blood Institute |
PLCO |
Jun 25, 2026 |
2026-8083 |
| ABO Blood Type and Secretor Status as Determinants of Oral Microbiome Composition and Cancer Risk: Evidence from the PLCO Cohort |
Emily Vogtmann |
National Cancer Institute |
PLCO |
Jun 18, 2026 |
PLCO-2058 |
| Longitudinal study of socioeconomic factors, stress-related biomarkers, and aggressive prostate cancer |
Kathryn Barry |
University of Maryland, Baltimore |
PLCO |
Jun 17, 2026 |
2026-0158 |
| Multi-population study of serum protein biomarkers and prostate cancer risk |
Sonja Berndt |
National Cancer Institute |
PLCO |
Jun 17, 2026 |
2026-0154 |
| Leveraging antibody responses against transposable elements as a novel immune therapy for ovarian cancer |
Rebecca Lynch |
The George Washington University School of Medicine and Health Sciences |
PLCO |
Jun 17, 2026 |
2026-0096 |
